Pfizer's 2024 Comeback: A Dividend Gem in the Pharma Market

Interestingly, there are no Big Pharma companies listed in the “Magnificent Seven.” Consequently, perfectly good companies like Pfizer (NYSE:PFE) are being overlooked, but that’s not bad news at all. If you appreciate a good value and like to collect dividends, stick around as today’s Pfizer stock analysis will bring you a “magnificent” pick for 2024. Now, I’m not going to claim that Pfizer is a problem-free company. It’s important to be aware of Pfizer’s challenges. However, without problems, there would b ...